Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
J. E. Crowe, M. Doyle, J. R. Genualdi, A. Bailey, N. Kose, C. Gainza, J. Rodriguez, K. M. Reeder, C. A. Nelson, P. N. Jethva, R. E. Sutton, R. G. Bombardi, M. Gross, J. G. Julander, D. H. Fremont, M. Diamond
The paper isolates a human monoclonal antibody that neutralizes yellow fever virus and provides therapeutic protection in animal models.
bioRxiv · Feb 28, 2022Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe
The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.
bioRxiv · Jan 12, 2022 · PreprintImmunology
A. R. Shiakolas, N. Johnson, K. J. Kramer, N. Suryadevara, D. Wrapp, S. Periasamy, K. A. Pilewski, N. Raju, R. Nargi, R. E. Sutton, L. Walker, I. Setliff, J. E. Crowe, A. Bukreyev, R. H. Carnahan, , I. S. Georgiev
This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.
bioRxiv · Jun 2, 2021 · PreprintImmunology
K. J. Kramer, N. V. Johnson, A. R. Shiakolas, N. Suryadevara, S. Periasamy, N. Raju, J. K. Williams, D. Wrapp, S. J. Zost, C. M. Holt, C.-L. Hsieh, R. E. Sutton, A. Paulo, E. Davidson, B. J. Doranz, , I. S. Georgiev
This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.
bioRxiv · May 16, 2021Immunology
E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe
The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.
bioRxiv · May 2, 2021Immunology
P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe
This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.
bioRxiv · May 2, 2021 · PreprintImmunology
E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond
This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.
bioRxiv · Dec 28, 2020Immunology
A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev
The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.
bioRxiv · Dec 20, 2020 · PreprintImmunology
A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom
This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.
bioRxiv · Sep 10, 2020Microbiology
S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe
The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.
bioRxiv · May 22, 2020Immunology
S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe
This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.
bioRxiv · May 12, 2020Immunology